FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

16 letters match. Newest first.

  1. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  2. Nanjing Hanxin Pharmaceutical Technology Co. Ltd.

    FDA warns Nanjing Hanxin of drug-ingredient quality failures and poor supplier oversight; its drugs face U.S. import detention.

    High risk
  3. Chongqing Qiancan Technology Co., Ltd.

    Chongqing Qiancan Technology, an API maker in China, refused FDA records requests; FDA placed its drugs on import alert 66-79.

    High risk
  4. Tianjin Healthcare Medical Technology Co., Ltd.

    Chinese API maker refused FDA records requests, and all its drugs now face a US import alert.

    High risk
  5. Guangdong Bisutang Biotechnology Co., Ltd.

    Guangdong Bisutang Biotechnology refused FDA records requests for OTC drugs and used a cancelled color additive in sunscreen.

    High risk
  6. Sanrace Biotechnology Co., Ltd.

    FDA warns Sanrace Biotechnology over CGMP failures in OTC drugs, including missing identity tests and no process validation.

    High risk
  7. TSP Solutions Pte. Ltd.

    FDA warns Singapore OTC drug maker TSP Solutions over missing release testing and component identity checks for sunscreens.

    High risk
  8. Zhejiang Gaorong Cosmetic Co., Ltd.

    FDA cited Zhejiang Gaorong Cosmetic for OTC drug CGMP violations in component testing and quality unit oversight.

    High risk
  9. Jiangmen Shuizirun Sanitary Articles Co., Ltd.

    FDA warns Chinese OTC drug maker Jiangmen Shuizirun for labeling products sterile without sterilizing them or testing for sterility.

    High risk
  10. Babikian Healthcare Products CJSC

    FDA warns Babikian Healthcare Products over manufacturing quality failures for over-the-counter drugs, including missing identity and finished-product testing.

    High risk
  11. VeganicSKN Limited

    FDA warns VeganicSKN over manufacturing rule failures; drug shipped after failing test and high-risk ingredient not identity-tested.

    High risk
  12. Reliance Life Sciences Private Limited

    FDA warned India's Reliance Life Sciences over falsified microbiology records and aseptic failures in sterile drug production, prompting a recall.

    High risk
  13. Shoolin Pharma Chem LLP

    Shoolin Pharma Chem, an Indian API maker, warned over filthy conditions, missing test data, and cleaning failures; all U.S. APIs recalled.

    High risk
  14. Tianjin Kilo Pharmaceutical Sci-tech Co., Ltd.

    Tianjin Kilo Pharmaceutical Sci-tech, a drug ingredient maker, cited for quality failures and missing listings for demecarium bromide and chlorambucil.

    High risk
  15. Dabur India Limited

    FDA cites Dabur India for falsified records, incomplete lab data, and inadequate cleaning and process validation for over-the-counter drugs.

    High risk
  16. Flowchem Pharma Private Limited

    FDA warned India's Flowchem Pharma over dirty API equipment, exposed materials and untested impurities, and blocked its drug imports.

    High risk